Cloudbreak Pharma Inc. reported no changes in the total authorized share capital during February 2026, with 2,000,000,000 ordinary shares authorized at a par value of USD 0.0001 each, resulting in a total authorized capital of USD 200,000.

The issued shares remained at 850,122,081, with none held in treasury. The minimum public float threshold of 25% was satisfied at the end of the month.

No increase or decrease in share issuances or treasury shares was noted. The company’s equity incentive plans, including Series B, Series C, the 2023 Equity Incentive Scheme, and the Post-IPO Equity Incentive Scheme, indicated no new shares issued or transferred out of treasury, with available shares remaining unchanged.